Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 51.4 -6.8 - View Chart
P/BV x 16.8 0.5 3,700.4% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs8,834126 7,016.8%   
Low Rs5,45861 8,932.1%   
Sales per share (Unadj.) Rs1,731.1301.8 573.6%  
Earnings per share (Unadj.) Rs211.9-24.9 -852.1%  
Cash flow per share (Unadj.) Rs219.92.5 8,641.2%  
Dividends per share (Unadj.) Rs65.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs945.2293.3 322.3%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.10.3 1,332.4%   
Avg P/E ratio x33.7-3.8 -896.9%  
P/CF ratio (eoy) x32.536.7 88.4%  
Price / Book Value ratio x7.60.3 2,371.3%  
Dividend payout %30.70-   
Avg Mkt Cap Rs m151,8481,154 13,160.8%   
No. of employees `0003.50.9 376.8%   
Total wages/salary Rs m4,356393 1,108.1%   
Avg. sales/employee Rs Th10,555.54,026.1 262.2%   
Avg. wages/employee Rs Th1,249.9425.0 294.1%   
Avg. net profit/employee Rs Th1,292.2-331.8 -389.5%   
INCOME DATA
Net Sales Rs m36,7863,724 987.8%  
Other income Rs m1,13323 5,035.1%   
Total revenues Rs m37,9193,747 1,012.1%   
Gross profit Rs m6,047395 1,531.7%  
Depreciation Rs m169338 50.0%   
Interest Rs m23354 6.4%   
Profit before tax Rs m6,989-275 -2,538.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,48532 7,864.6%   
Profit after tax Rs m4,503-307 -1,467.4%  
Gross profit margin %16.410.6 155.1%  
Effective tax rate %35.6-11.5 -309.8%   
Net profit margin %12.2-8.2 -148.5%  
BALANCE SHEET DATA
Current assets Rs m27,6102,638 1,046.7%   
Current liabilities Rs m8,5692,305 371.8%   
Net working cap to sales %51.88.9 578.8%  
Current ratio x3.21.1 281.5%  
Inventory Days Days60135 44.5%  
Debtors Days Days2746 59.1%  
Net fixed assets Rs m1,0574,871 21.7%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m19,8733,496 568.5%   
Net worth Rs m20,0863,619 555.0%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m29,4097,509 391.7%  
Interest coverage x311.60.2 139,746.7%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.5 252.2%   
Return on assets %15.40.6 2,437.7%  
Return on equity %22.4-8.5 -264.4%  
Return on capital %34.91.6 2,206.3%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m4,918517 952.3%   
Net fx Rs m-4,549-517 880.8%   
CASH FLOW
From Operations Rs m4,991514 970.3%  
From Investments Rs m-2,570-123 2,087.7%  
From Financial Activity Rs m-1,428-387 368.9%  
Net Cashflow Rs m9934 23,650.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare ABBOTT INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 163 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

It was indeed a volatile trading day for share markets in India today. After staging a gap-up opening, Indian share markets reversed gains.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 21, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - J.B.CHEMICALS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS